Imaging heterogeneity in the mitochondrial redox state of premalignant pancreas in the pancreas-specific PTEN-null transgenic mouse model by unknown
Xu et al. Biomarker Research 2013, 1:6
http://www.biomarkerres.org/content/1/1/6RESEARCH Open AccessImaging heterogeneity in the mitochondrial
redox state of premalignant pancreas in the
pancreas-specific PTEN-null transgenic mouse
model
He N Xu1,2, Shoko Nioka2 and Lin Z Li1,2*Abstract
Background: Metabolic alteration is one of the hallmarks of carcinogenesis. We aimed to identify certain metabolic
biomarkers for the early detection of pancreatic cancer (PC) using the transgenic PTEN-null mouse model.
Pancreas-specific deletion of PTEN in mouse caused progressive premalignant lesions such as highly proliferative
ductal metaplasia. We imaged the mitochondrial redox state of the pancreases of the transgenic mice
approximately eight months old using the redox scanner, i.e., the nicotinamide adenine dinucleotide/oxidized
flavoproteins (NADH/Fp) fluorescence imager at low temperature. Two different approaches, the global averaging
of the redox indices without considering tissue heterogeneity along tissue depth and the univariate analysis of
multi-section data using tissue depth as a covariate were adopted for the statistical analysis of the multi-section
imaging data. The standard deviations of the redox indices and the histogram analysis with Gaussian fit were used
to determine the tissue heterogeneity.
Results: All methods show consistently that the PTEN deficient pancreases (Pdx1-Cre;PTENlox/lox) were significantly
more heterogeneous in their mitochondrial redox state compared to the controls (PTENlox/lox). Statistical analysis
taking into account the variations of the redox state with tissue depth further shows that PTEN deletion
significantly shifted the pancreatic tissue to an overall more oxidized state. Oxidization of the PTEN-null group was
not seen when the imaging data were analyzed by global averaging without considering the variation of the redox
indices along tissue depth, indicating the importance of taking tissue heterogeneity into account for the statistical
analysis of the multi-section imaging data.
Conclusions: This study reveals a possible link between the mitochondrial redox state alteration of the pancreas
and its malignant transformation and may be further developed for establishing potential metabolic biomarkers for
the early diagnosis of pancreatic cancer.
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Pancreatic cancer ranking the fourth leading cause of
cancer-related deaths in the United States has the inci-
dence rate approaching the mortality rate [1,2]. The main
reason is that at the time of diagnosis 80-85% patients are
already present with locally advanced or metastatic disease
that prevents curative surgery [3-5]. The etiology of PC is
unclear and more than 90% of PC patients acquire the di-
sease sporadically. The early detection of PC is therefore
critical to improving the survival rate and reducing the
mortality rate. Currently there is no reliable biomarker
available for the early diagnosis of PC. Although the most
common biomarker for PC, serum carbohydrate antigen
19-9 (CA 19-9) secreted by the exocrine pancreas cells
has up to 90% specificity to symptomatic patients, low
positive predictive value in asymptomatic patients, false
negative results in Lewis negative phenotype, and in-
creased false positivity in the presence of obstructive jaun-
dice limit its usefulness for the early detection of PC [6].
Advances in the technology are of crucial importance to
provide the new biomarkers sensitive and specific to PC
[7,8]. Since only about 10% PC patients present diagnostic
genetic mutations, studies searching for biomarkers for
the early detection ought to look beyond these signature
mutations.
Cancer metabolism has received renewed research inte-
rest in recent years and metabolic alteration has been
recognized as a cancer hallmark [9-16]. Metabolic bio-
marker, such as fluorinated deoxy-glucose (FDG) has been
a great aid for the diagnostic purpose of many forms of
cancer. However, FDG presents a few limitations when
applied to the early detection of pancreatic cancer (PC)
[17]. Exploring other cancer biomarkers that are sensitive
and specific to PC based on its altered metabolism is ob-
viously worth the effort.
Metabolic changes are reflected in the cellular redox
state that is essential for many biological functions in-
cluding cell growth, differentiation, survival, apoptosis,
motility, invasiveness, transcription, and signaling [18].
For instance, alterations in glucose metabolism affect
both cytosolic and mitochondrial redox potential [12].
Reprogramming of cellular metabolism by metabolic
mutations can also facilitate oncogenesis [19]. Three
metabolic enzymes, isocitrate dehydrogenase, succinate
dehydrogenase and fumarate hydratase essential in the
TCA cycle in the mitochondria acted as an oncogene or
tumor suppressors and their mutations were associated
with some forms of cancer [19-21]. The reactions cata-
lyzed by these enzymes are driven by the redox poten-
tials, and it is likely that these mutations may also alter
the cellular redox state [22].
We previously employed the NADH/Fp fluorescence
redox scanning technique [23-27] to probe the possible
link between the mitochondrial redox state and tumorprogression. NADH and Fp (including flavin adenine di-
nucleotide FAD) fluorescence are sensitive to the mito-
chondrial metabolism and their ratios, e.g., Fp/NADH or
Fp/(Fp +NADH) are good indicators of the mitochondrial
redox state [23,24,28-31]. Our results showed that the
mitochondrial redox indices (NADH, Fp, and Fp/(Fp +
NADH)) displayed distinct heterogeneities in human me-
lanoma and breast cancer in mouse models and the ag-
gressive tumors have localized regions with more oxidized
redox state compared to the indolent ones [18,32-35].
It has also been reported that redox-sensitive autofluo-
rescence imaging could be applied for metabolic cha-
racterization of premalignancy. For example, marked
changes in the redox state in the dysplastic tissue were
observed in one third of human premalignant cervical
biopsy samples [36]. Using two-photon technique the
redox states of precancerous epithelia of oral cancer
were evaluated, showing significant changes for mito-
chondrial NADH but not for volume-averaged redox
ratio (FAD/NADH) [37]. Additionally, researchers
imaged the snap-frozen biopsy samples of human cer-
vical tissues using the redox scanner and showed that
the dysplastic tissue was significantly more heteroge-
neous in the mitochondrial redox state in the stromal
regions than the normal or inflammatory tissues [38].
However, it is not clear whether redox state change,
more specifically to our interest, the mitochondrial
redox state alteration, is required for cancer transform-
ation and progression and if so, to what degree. Also,
little is known about the interaction between the mito-
chondrial redox state and the signaling pathways. To
investigate whether the mitochondrial redox state alter-
ation is associated with cancer transformation and to
identify the potential imaging biomarkers for pancreatic
pre-malignancy, we chose to characterize the mitochon-
drial redox state of a PTEN-null transgenic mouse model
[39] by redox scanning. In this model, pancreas-specific
PTEN deletion caused pancreatic metaplasia, where the
acinar pancreas is progressively replaced with highly pro-
liferative ductal structures and a fraction of the mice
develop ductal malignancy. It is known that metaplasia is
a harbinger of cancer in many tissues [40-42]. Metasplas-
tic tissue may progress into dysplastic and then malignant
neoplastic tissue. Therefore, pancreas-specific PTEN dele-
tion provides an excellent model system to study how the
normal tissue is transformed to certain type of PC.
Some of the preliminary results of this study have been
reported elsewhere [43]. In this paper, we present the
detailed quantitative findings from imaging the mito-
chondrial redox state in the premalignant pancreas. Our
analyses showed that PTEN deletion slightly shifted the
mitochondrial redox state to the more oxidized state
and caused tissue to become more heterogeneous in the
mitochondrial redox state with localized small regions
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that the mitochondrial redox imaging indices provide sensi-
tive biomarkers for early detection of PC. Additionally, our
work also demonstrates that quantitative analysis account-
ing for tissue heterogeneity is highly needed to extract rele-
vant rich biological information for tissue imaging whereas
volume-average/global average tends to minimize such
information.
Results
PTEN deletion rendered the pancreases to become more
heterogeneous in the mitochondrial redox state
We set out to examine the relationship between the pre-
malignant pancreatic tissues and their mitochondrial
redox states by imaging the Fp and NADH fluorescence
signals of the premalignant group and the control group.
From these images, we generated the redox indices: Fp,
NADH, Fp redox ratio (Fp/(NADH+ Fp)), Fp/NADH,
and NADH/Fp and their standard deviations (SD) forFigure 1 PTEN-null pancreas (transversal and coronal sections). Typica
histograms of a pancreas in the PTEN-null group. The top two rows are the
two rows are the coronal section with a milling depth 340 μm. The mean
nominal concentration (μM), NADH nominal concentration (μM), Fp redox
images indicate the nominal concentrations in μM. The color bars of the F
the pseudo-color images are the dimension of scan matrix, representing th
probe. The x axes of the corresponding histograms represent the Fp or NA
pixels in the tissue section having a specific value of fluorophore concentrafurther statistical analyses. We discovered that the redox
states in the premalignant tissue (PTEN-null group) were
highly heterogeneous as shown by the wide distribution in
their histograms of the ratio indices (Figure 1). In contrast,
the control group had relatively more homogenous redox
states with smaller SDs of the Fp redox ratio, Fp/NADH,
and NADH/Fp as evidenced by the narrower width in the
corresponding histograms (Figure 2). In Figure 3, to show
greater image details, we magnified the typical areas from
the Fp redox ratio images in Figures 1 & 2. It is clearly
seen from Figure 3 that PTEN deficiency caused the tissue
to be more heterogeneous in the Fp redox ratio with lar-
ger standard deviation.
To assess the tissue heterogeneity by the standard
deviations of the redox indices, we used two statistical
methods, Method I and Method II (see Materials and
Methods section). Method I takes a global average across
multiple imaging sections of a sample, whereas Method
II includes results from each section for the analysis.l pseudo-color images of the redox indices and their corresponding
transversal section with a milling depth of 400 μm and the bottom
values and SDs are shown on each histogram. From left to right: Fp
ratio, Fp/NADH, and NADH/Fp. The color bars of the Fp and NADH
p redox ratio images indicates the ratio range from 0-1. The x-y axes of
e physical location of the tissue relative to the origin of the fiberoptic
DH concentration or their ratios. The y axes represent the number of
tion or ratio. Image resolution: 100 μm.
Figure 2 Control pancreas (transversal and coronal sections). Typical pseudo-color redox images and their corresponding histograms of a
pancreas in the control group. The top two rows are the transversal section with a milling depth 800 μm and the bottom two rows are the
coronal section with a milling depth of 800 μm. Image resolution: 100 μm.
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istical difference because of the loss of heterogeneity infor-
mation with global averaging. The results are summarized
in the lower panels of Tables 1 & 2. Both methods revealed
that the Fp redox ratio of the PTEN-null group were much
more heterogeneous with significantly larger standard
deviations compared to the control group. By Method I,
the SD of the Fp redox ratio is 0.05 ± .02 and 0.10 ± .01
for the control and PTEN null group, respectively with p =
0.01 by the two-tailed t-test. By Method II, the SD of the
Fp redox ratio is 0.06 ± .02 and 0.10 ± .01 for the control
and PTEN-null group, respectively with p < 0.001, more
significant than that of Method I.
We also adopted a different approach to assessing the
heterogeneity of the Fp redox ratio, where each histo-
gram of the Fp redox ratios was fitted with two Gaussian
functions (Figure 4) (see Materials and Methods sec-
tion). Both fitting coefficients c1 and c2, thus the widths
of the Gaussian curves FWHM1 and FWHM2 exhibited
a significant difference between the two groups by both
Method I and II (Table 3). FWHM or c depicts the bell
shape of a Gaussian curve. A larger FWHM or c means
the curve is “fatter”, otherwise “skinner”. Larger c1 and
c2 in the Gaussian curves of Fp redox ratio delineatesthe wider distribution of the redox state or a larger stand-
ard deviation for the mean value of redox ratios. Therefore,
the PTEN-null group having significantly larger ci coeffi-
cients was much more heterogeneous in the redox state.
There is no significance difference between two groups in
either b1 or b2 representing the centers of the Fp redox
ratio values of the two Gaussian peaks. The fitting coeffi-
cients a1 and a2 are proportional to the number of pixels
or areas of each Gaussian fit and are tissue-size dependent.
Their ratio, a2/a1, which is the area ratio of the two Gauss-
ian curves is a more meaningful comparison. There is no
significant difference in a2/a1 between the two groups.
Analysis performed with both Method I and II indicates
no significant difference in a2/a1 between the two groups.
PTEN deletion shifted the pancreases to a more oxidized
mitochondrial redox state.
When taking tissue depth into account, the difference in
Fp, NADH, the Fp redox ratio, and Fp/NADH between
the two groups becomes statistically significant by Method
II (Table 2). The two ratio indices, the Fp redox ratio and
Fp/NADH became larger due to PTEN deletion, where
the Fp redox ratio increased from 0.31 ± 0.04 to 0.37 ± .08
(p = 0.01) and Fp/NADH increased from 0.53 ± 0.09 to
Figure 3 The magnified areas indicated in the red squares of the Fp redox ratio images in Figures 1 & 2. Left-PTEN-null; Right-Ctrl.
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PTEN deletion had shifted the pancreases to an overall
more oxidized redox state. In comparison, Method I does
not show any significant difference in the redox ratio indi-
ces between the PTEN-null and control groups. In terms
of concentration, the PTEN-null group has only about half
amount of Fp (p = 0.002) or NADH (p < 0.001) compared
with the control group (Method II).Table 1 The redox indices (mean ± SD) and their standard de
Fp NADH
Ctrl (N = 3, 9 sections) 290 ± 88 568 ± 134
PTEN-null (N = 3, 14 sections) 171 ± 27 294 ± 40
p 0.13 0.06
SD(Fp) SD(NADH)
Ctrl (N = 3, 9 sections) 78 ± 32 151 ± 37
PTEN-null (N = 3, 14 sections) 82 ± 15 158 ± 64
p 0.89 0.88Discussion
Possible link between the mitochondrial redox state
alteration and cancer transformation
We imaged the mitochondrial redox indices of the PTEN-
null mouse model using the redox scanner to look for
potential new biomarkers for pre-malignancy detection. To
support their rapid growth and survival in stressful and
dynamic microenvironment, cancer cells constitutivelyviations (mean ± SD) (Method I)
Fp Redox Ratio Fp/NADH NADH/Fp
0.34 ± .02 0.53 ± .04 2.07 ± .12
0.39 ± .07 0.73 ± .22 1.92 ± .60
0.34 0.25 0.71
SD(Fp Redox Ratio) SD(Fp/NADH) SD(NADH/Fp)
0.05 ± .02 0.14 ± .06 0.44 ± .14
0.10 ± .01 0.39 ± .14 0.82 ± .18
0.01 0.08 0.05
Table 2 The redox indices (mean ± SD) and their standard deviations (mean ± SD) (Method II)
Fp NADH Fp Redox Ratio Fp/NADH NADH/Fp
Ctrl (N = 3, 9 sections) 298 ± 113 581 ± 181 0.31 ± .04 0.53 ± .09 2.06 ± .32
PTEN-null (N = 3, 14 sections) 167 ± 49 301 ± 101 0.37 ± .08 0.69 ± .26 2.01 ± .73
p 0.002 <0.001 0.01 0.003 0.17
SD(Fp) SD(NADH) SD(Fp Redox Ratio) SD(Fp/NADH) SD(NADH/Fp)
Ctrl (N = 3, 9 sections) 82 ± 33 156 ± 45 0.06 ± .02 0.15 ± .06 0.47 ± .16
PTEN-null (N = 3, 14 sections) 81 ± 23 168 ± 72 0.10 ± .01 0.37 ± .15 0.85 ± .28
p 0.79 0.53 <0.001 <0.001 0.006
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verge to adapt/alter core cellular metabolism of all four
major classes of macromolecules: carbohydrates, proteins,
lipids, and nucleic acids. As one of the key oncogenic sig-
naling pathways, PI3K/AKT pathway has profound effects
on the metabolism of cancer cells [9]. It regulates glucose
uptake and utilization and its activation renders cells
dependent on high levels of glucose flux [15]. The down-
stream molecule NF-κB in the PI3K/AKT pathway controls
the balance between the utilization of glycolysis and mito-
chondrial respiration [44]. Studies show that up to 60% of
pancreatic cancers have either amplified or activated AKT2
kinase [45-47]. PTEN is a negative regulator of PI3K/AKT
pathway. PTEN mutations amplify PI3K/AKT signaling and
promote tumorigenesis. For example, it is shown that ge-
nomic deletion of PTEN is associated with prostate tumor
metastatic potential [48]. However, the in vivo metabolic
evaluation on the role of activated PI3-K/AKT signaling in
the initiation or progression of pancreatic cancer has not
been reported.
Our results showed that the PTEN-null pancreases
had many regions with higher values of the Fp redox
ratio (as typically seen in Figures 1 & 3). The heteroge-
neity markers such as the SDs or the histogram widths
(ci) of the Fp redox ratio, Fp/NADH, and NADH/Fp are
significantly larger in the PTEN-null pancreases,
whereas the tissues in the control group were relativelyCurve fit of the Fp redox ratio histogram 
























Figure 4 Gaussian fit of the Fp redox ratio histogram. Typical fits (red
coronal sections in Figures 1 & 2 by the sum of two Gaussian functions (grmore homogeneous with significantly smaller SDs and
smaller Gaussian curve width ci (Tables 1, 2 and 3). Higher
level of metabolic heterogeneity is consistent with pre-
vious observations on various pre-cancer tissues [37,38].
Therefore, it is likely that heterogeneous mitochondrial
redox state is associated with cancer transformation. This
indicates that (pre)malignant tissues may exhibit signifi-
cant mitochondrial redox abnormality in localized spots
before fully transformed.
We also observed lower levels of Fp and NADH in the
PTEN-null group (Table 2). Decreased Fp and NADH is
probably partially due to decreased cell density in pre-
malignant tissues which had various sizes of ductal
structures and cystic dilations [39]. The ratio indices that
represent the metabolic and redox states of the tissues,
Fp/NADH, NADH/Fp, or Fp/(Fp + NADH) and their
standard deviations are less sensitive to the variability of
cell density. A few other factors could affect Fp and
NADH fluorescence signals, such as blood circulation
and instrument fluctuations. Ratiometric indices such as
the redox ratios are largely insensitive to these factors.
Notably, only the SDs of the ratio indices distinguished
between two groups whereas the SDs of Fp and NADH
did not. This suggests that the heterogeneity of the ratio
indices may be a better marker than the heterogeneity of
Fp and NADH for the identification of premalignant
tissues.Curve fit of the Fp redox ratio histogram 
























line) of the histograms of the Fp redox ratios (black dots) in the
een & pink lines). Left: control; Right: PTEN-null.
Table 3 The fitting Gaussian coefficients (mean ± SD) of the Fp redox ratios
a1 a2 b1 b2 c1 c2 a2/a1
Method I Ctrl (N = 3, 9 sections) 54 ± 30 33 ± 24 0.31 ± .02 0.35 ± .02 0.032 ± .003 0.065 ± .01 0.72 ± .47
PTEN-null (N = 3, 14 sections) 39 ± 15 24 ± 10 0.32 ± .06 0.37 ± .04 0.071 ± .006 0.12 ± .02 0.84 ± .22
p 0.49 0.59 0.91 0.53 0.001 0.018 0.71
Method II Ctrl (N = 3, 9 sections) 52 ± 36 36 ± 27 0.31 ± .03 0.34 ± .04 0.033 ± .01 0.07 ± .02 0.82 ± .50
PTEN-null (N = 3, 14 sections) 38 ± 28 23 ± 16 0.32 ± .13 0.38 ± .12 0.074 ± .04 0.13 ± .04 0.84 ± .86
p 0.067 0.04 0.39 0.13 0.004 0.001 0.87
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deletion shifted the tissue to a more oxidized state. Sig-
nificantly higher Fp redox ratio and Fp/NADH were
found in the PTEN-null group compared to the control
group (Table 2). Higher Fp redox ratio or Fp/NADH was
not reported previously by other researchers on various
pre-cancer tissues [36-38]. For example, one of the stu-
dies imaged the redox ratios at various tissue depths for
precancerous epithelia of oral cancer [37], and no sig-
nificant difference was found in the redox ratios when
comparing global averages between the precancerous
and normal tissues. This is exactly what we have seen
using Method I analysis. However, we saw statistically
significant difference when using Method II that takes
tissue depth as a covariate in GLM analysis. Another
study [38] measured the 3D distribution of the redox
state in fast-frozen human cervical tissues that typically
consisted of an upper epithelium and a lower stroma.
When compared to the normal tissue, the dysplastic epi-
thelia had decreased redox ratio whereas the stroma
appeared to have increased redox ratio (estimated based
on their reported data [26]). However, it was not
reported whether there was any difference in the overall
averages of the redox ratios of the entire tissue block.
The other study [36] measured the autofluorescence sig-
nals to investigate the redox state in the clinical cervical
tissue samples that have been kept under temperatures
above 0°C for 1.5-5 hours before imaging. Reduced
redox ratios were found in the dysplastic epithelia of one
third of the patient samples compared to the paired nor-
mal samples. During the long waiting period before im-
aging, the intrinsic fluorescence signal and the redox
state in the tissue samples might have changed signifi-
cantly and differential changes between the precancerous
and the normal tissues might have occurred. In contrast,
the mice’s pancreases used in our study were resected
and dropped in liquid nitrogen within two seconds, and
have been kept in liquid nitrogen for storage and during
the redox scanning process. Their mitochondrial redox
states should be the same as or very similar to the
in vivo condition due to the snap-freezing procedure.
Nevertheless, the slightly higher Fp redox ratio in the
PTEN-null group appears to be consistent with our pre-
vious studies on the redox states of the normal tissueand indolent and aggressive tumor tissues [26,32-34].
The normal muscle tissues had lower Fp redox ratio
compared with the cancer tissues. The aggressive tumors
exhibited a readily-recognized bi-modal distribution of
their redox indices (e.g. Fp, NADH, Fp redox ratio) with
substantial regions having significantly higher Fp redox
ratio, i.e., more oxidized redox state, whereas the indo-
lent tumors had relatively homogeneous and reduced
redox states. The more aggressive the tumors were, the
more heterogeneous they were and higher Fp redox ratio
in the oxidized regions. Thus, the results of this study
provide more evidence to a link between malignant trans-
formation/progression and a more oxidized and heteroge-
neous mitochondrial redox state.
However, the role of the mitochondrial redox state in
cancer transformation/progression remains largely unclear.
Connections between the redox potentials (or NADH
levels) and malignancy have been implicated in some stud-
ies [49-54]. High levels of free radicals/oxidants are known
to generate oxidative damages and genetic mutations that
may drive cancer transformation/progression. The mito-
chondrion is one of the major sources of free radical gener-
ation. Mitochondrial dysfunctions have been shown to
induce overproduction of reactive oxygen species (ROS),
which increases metastatic potential of cancer cells [51,55]
and drives tumor transformation/progression in surround-
ing tissues in conjunction with oncogenic Ras [56]. How-
ever, ROS-independent pathways may also exist [57].
Nevertheless, high levels of free radicals/oxidants do not
necessarily indicate oxidized redox potential. The high
levels of oxidants in tumors are often counter-balanced by
high levels of reductants such as vitamin C, reduced gluta-
thione, and reduced nicotinamide adenine dinucleotide
phosphate (NADPH) [53,58-60]. Cellular redox potential,
i.e., the balance between reductants and oxidants, is me-
diated by multiple intracellular redox couples, e.g. NAD
+/NADH, NADP+/NADPH, and oxidized/reduced glutathi-
one. Redox biology is further complicated by the uneven
distributions of redox systems in subcellular compartments
(cytosolic, nuclear, mitochondrial, etc.). The mitochondrial
redox potential may or may not be coupled with the cyto-
solic redox potential [61]. If we can accurately and pre-
cisely quantify the intracellular redox potential in each
subcellular compartment, then it is possible to have a
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chondrial redox state and cancer transformation/progres-
sion as evidenced by our studies.
Importance of imaging intratumor heterogeneity by
submillimeter imaging methods
It is known that concentrations of crucial nutrients such
as glucose, glutamine, and oxygen are spatially and tem-
porally heterogeneous in solid tumors [9,10]. Intratumor
heterogeneity is an important factor for cancer diagnosis
and treatment. The variability among subpopulations of
tumor cells is well known for tumor progression and
such heterogeneity is associated with malignancy and
metastasis [62-65] as well as treatment failure [66]. Stu-
dies also showed that tissue heterogeneity is indicative of
malignant phenotypes [67,68]. Imaging tumor heterogen-
eity may grade tumor invasive/metastatic potential and
yield important prognostic and/or predictive biomarkers
[32,33,69]. Promisingly, imaging pre-cancer tissues also
revealed the existence of metabolic heterogeneity in dys-
plastic/premalignant tissues [36-38].
Since the tissue metabolic heterogeneity may be on a
submillimeter scale [18], other metabolic biomarkers such
as FDG-PET with a spatial resolution on the order of
millimeters [70,71] are incapable of resolving it. Therefore,
it is important to study tissues by using a high resolution
imager. The redox scanner [24,27] we employed has a
spatial resolution down to 50 × 50 × 20 μm3. As shown by
the present study, the submillimeter high resolution redox
imaging of tissue heterogeneity enhances the capability to
identify biological factors that are important for cancer
transformation but may not be seen by low resolution i-
maging techniques or the measurements of tissue homo-
genates. It should also be noted that the snap-freezing of
the pancreases right after resection ensured the redox
state of the frozen tissues is the same as or very similar to
that of the in vivo condition.
Selection of proper analysis methods to account for
tissue heterogeneity
In our previous studies, when averaging over entire
tumor, the heterogeneity information was largely lost,
resulting in less significant or insignificant difference in
Fp redox ratio between the aggressive and indolent
tumors [32,33]. Consistently, we did not see significant
difference in the Fp redox ratio between the premalig-
nant and the control group after the global averaging for
each pancreas using Method I that largely ignores the
spatial heterogeneity of these redox indices. However,
the redox images show that tissue heterogeneity exists in
three dimensions in both the PTEN-null and control
groups, with the PTEN-null group having a distinctly
higher level of heterogeneity as evidenced by both image
visualization (Figures 1, 2 and 3) and the quantificationsof the standard deviations and widths of the Gaussian fits.
The global averaging in Method I effectively removed the
information on tissue heterogeneity and also reduced the
number of independent data for statistical analysis. Thus,
global average does not truly represent the heterogeneous
nature of the diseased tissues, which may be critically im-
portant for distinguishing between groups.
Compared to Method I, Method II recognizes tissue
heterogeneity in one of the three dimensions by using
tissue depth (z-direction) as a covariate for the statistical
analysis. Each tissue section has a tissue depth that is
the distance between the top section and the specified
section. Increased statistical significance was observed
using Method II, yielding much smaller p values for the
differences of the means between the PTEN-null and
control groups. For example, a significant p value of 0.01
was reached for comparing the means of the Fp redox
ratios from Method II whereas Method I failed to statis-
tically differentiate Fp redox ratios between two groups.
The difference between Method I and II shows the im-
portance of selecting proper statistical analysis method
for comparing multi-slice imaging results.
This result also shows the advantage of imaging mea-
surements compared with the common practice that mea-
sures tissue homogenates where tissue has been ground
and mixed to be homogenized [61,72,73]. We observed
high heterogeneity of the redox state in both coronal and
transversal planes of PTEN-null pancreases and along tis-
sue depth. As heterogeneity is one of the very important
characteristics of pathological tissues including precance-
rous tissues, the more tissue heterogeneity information is
acquired, the better they are characterized. Suitable statis-
tical analysis methods are also needed to account for the
heterogeneity in three dimensions.
One of the shortcomings of the study is that the
spatial resolution of the redox images of 100 μm used in
this study is still not capable of fully resolving the pan-
creas premalignant lesions involving the highly prolifera-
tive ductal formations (size on the order of ~200 μm). In
future, we may use CCD based redox imaging techni-
ques to advance the study at a higher spatial resolution.
We may also co-register the redox images with the
histological staining and incorporate the in-depth studies
on the biology to identify the sources of those more oxi-
dized spots.
Conclusions
In this paper we presented the redox imaging data with
detailed analyses on the mitochondrial redox state of the
normal pancreases and the PTEN-null pancreases that
had developed premalignant lesions. The results showed
that the PTEN deficiency had significantly altered the
mitochondrial redox state of the pancreatic tissue. The
mitochondrial redox state in pancreas became more
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negative regulator of PI3K/AKT pathway. Such alteration
in the mitochondrial redox state may provide possible bio-
markers for early cancer detection. Although the current
redox scanning method is applicable to clinical specimens,
non- or minimal-invasive imaging methods for measuring
tissue mitochondrial redox state in vivo should be deve-
loped in future.
Furthermore, this is the first study that showed possible
link between pancreatic pre-malignancy and mitochon-
drial redox state alteration in pancreas. This study sug-
gests that heterogeneous oxidization of the mitochondrial
redox state in pancreatic tissue could be associated with
cancer transformation. As the nature and importance of
metabolic alterations in cancer can be masked by excess
oxygen and nutrients in cultured cells, this study also shed
light on cancer metabolism and the biology at tissue level.
Materials and Methods
Organ harvest and tissue sample preparation
Three pancreas-specific PTEN-null mice (Pdx-1-Cre;
PTENlox/lox) and three control mice (PTENlox/lox) were
prepared in Stanger’s laboratory [39]. The mice were
approximately eight months old. The pancreases of the
anesthetized mice were quickly resected during the open-
chest surgery and dipped into liquid nitrogen within two
seconds after removal. The samples for redox scanning
were prepared as previously described [33,74,75]. Briefly, a
snap-frozen pancreas was carefully placed into the mount-
ing medium composed of ethanol-glycerol-water that was
chilled below its freeze point -30°C and contained in a
plastic screw closure of 24 mm diameter. Frozen reference
standards (one NADH and one FAD in PBS buffer with
known concentrations) were quickly mounted adjacent to
the tissue. The embedded sample was then maintained in
liquid nitrogen awaiting redox scanning. All samples were
prepared the same way.
Redox scanning
The redox scanning was performed using the redox scan-
ner. Briefly, the sample immersed in liquid nitrogen was
first milled flat with a surface area of ≥ 3 × 3 mm2. The
bifurcated fiberoptic probe driven by a stepper motor
scanned across the surface. The Fp channel excitation and
emission filters were 430 ± 25 nm and 525 ± 32 nm, res-
pectively; and those of NADH channel were 360 ± 13 nm
and 430 ± 25 nm, respectively. Multiple sections at differ-
ent milling depths (ranging from 200-2340 μm below the
surface, i.e. the top section of a pancreas tissue) with spa-
cing 100-400 μm were scanned for each pancreas (9 and
14 sections from the control and the PTEN-null group, re-
spectively) with a scanning matrix being 128 × 128 and a
step size of 100 μm. The reference standards were also
scanned along with each tissue section.Data analysis
The acquired Fp and NADH signals were further analyzed
with a customized MatLabW program to generate the
needed images. The fluorescence intensities and concentra-
tions of the reference standards were used to convert the
tissue Fp and NADH fluorescence intensities to the corres-
ponding nominal concentrations [33,74,75]. Pixels having
SNR < 3.5 were excluded from the analysis. The mean
values and the standard deviations (SD) of all redox indi-
ces, i.e. NADH, Fp, Fp redox ratio (Fp/(Fp +NADH)), Fp/
NADH, and NADH/Fp were obtained for the region of
interest (ROI) for each image section.
The statistical difference of these indices and their
standard deviations between the PTEN-null and the con-
trol group was evaluated using two methods. Method I is
to first average a redox index from a specific section to
give the mean value of that section. The mean value for
each section of the same pancreas was obtained in the
same way. These mean values were then averaged to give
the mean value of the redox index of that pancreas. Group
mean value was obtained by averaging the mean value
across three pancreases and the corresponding standard
deviation was calculated. Two-taile, unpaired t-tests were
performed to compare a specific redox index between the
two groups, with p < 0.05 being considered statistically dif-
ferent. The same was performed for the standard devi-
ation of each redox index. The results are summarized in
Tables 1 & 2. Although it is straightforward, this method
loses information on the spatial heterogeneity of a specific
redox index across different sections of a pancreas.
In addition to the heterogeneity in each tissue section,
the mean value of each redox index also varies at different
tissue depth. Tissue depth is the distance between the top
section and the specified section. Method II uses the
GLM Univariate analysis (IBM SPSS Statistics, ver. 20)
with tissue depth as a covariate to evaluate whether the
values of these redox indices depend on the PTEN status
that is the independent variable. To perform this analysis,
the mean value of each redox index from each tissue sec-
tion was included as a sample of the dependent variables
(e.g. NADH, Fp, or the Fp redox ratio). P < 0.05 is taken as
statistically significant. The average tissue depth is 583 ±
257 μm and 927 ± 804 μm for the control and PTEN-null
group, respectively. There is no statistical difference in the
average of tissue depth between the two groups (p = 0.54).
The results obtained by Method II are reported in Tables 1,
2 & 3 as mean ± SD.Gaussian fit
The heterogeneity in Fp ratio was further quantitatively
characterized using the curve fit approach in MatlabW.









2 ) was used to fit the Fp redox ratio histogram
of each section, where parameter ai is the height of the
Gaussian function peak, bi is the position of the centre
of the peak, and ci controls the width of the "bell" shape
of the Gaussian curve (i = 1, 2). The full width at half





ci . The results and their statistical
analyses using the Method I and II are reported in
Table 3.
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